Navigation Links
Warner Chilcott Reports Operating Results for the Quarter and Year ended December 31, 2007
Date:2/29/2008

ease of $21.3 million, or 10.3%, over the prior year quarter. The primary drivers of the increase in revenue, as compared to the prior year quarter, were the net sales of two products, LOESTRIN 24 FE and TACLONEX.

Sales of our oral contraceptive products increased $8.4 million, or 13.9%, in the quarter ended December 31, 2007, compared with the prior year quarter. LOESTRIN 24 FE generated revenues of $41.6 million in the quarter ended December 31, 2007, compared to $21.5 million in the prior year quarter. The increase in revenues was primarily due to an increase of 93.8% in filled prescriptions for LOESTRIN 24 FE compared to the prior year quarter. Filled prescriptions of LOESTRIN 24 FE increased 6.5% sequentially in the quarter ended December 31, 2007, compared to the quarter ended September 30, 2007. We introduced and began commercial sales of FEMCON FE in the second half of 2006, but did not initiate promotional efforts in support of the product until April 2007. Beginning in April 2007, FEMCON FE became a promotional priority for our Chilcott sales force and generated revenues of $11.6 million in the quarter ended December 31, 2007, an increase of $4.1 million, or 53.3%, versus the prior year quarter. The increase in revenues was primarily due to a 200.0% increase in filled prescriptions for FEMCON FE compared to the prior year quarter. Filled prescriptions of FEMCON FE increased 15.0% sequentially in the quarter ended December 31, 2007 compared to the quarter ended September 30, 2007. Net sales of ESTROSTEP FE decreased $13.9 million, or 58.0%, in the quarter ended December 31, 2007 compared to the prior year quarter. The decrease in revenues was due to the introduction of generic versions of ESTROSTEP FE beginning in late October 2007, which lowered filled prescriptions of ESTROSTEP FE by 60.6% versus the prior year quarter. At the time of the launch of a generic version of ESTROSTEP FE, we partnered with Watson Pharma, Inc. to launch Tilia(TM) Fe, an a
'/>"/>

SOURCE Warner Chilcott Limited
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17

Related biology technology :

1. Warner Chilcott Announces Earnings Release Date and Conference Call for Fourth Quarter and Full Year 2007 Financial Results
2. Warner Chilcott and Watson Pharmaceuticals Announce Launch of Tilia(TM) Fe
3. Warner Chilcott Announces Earnings Release Date and Conference Call for Third Quarter 2007 Financial Results
4. Warner Chilcott Announces New Information in USPTO Reexamination of Taclonex Patent
5. Warner Chilcott Announces Receipt of Paragraph IV Certification Notice
6. Cepheid Reports Fourth Quarter and Full Year 2007 Results
7. Strategic Diagnostics Reports Fourth Quarter and Full-Year Financial Results
8. US Oncology Reports Fourth Quarter and Fiscal Year 2007 Results
9. Barr Reports GAAP Earnings of $1.18 Per Share for 2007 and $0.30 Per Share for the Fourth Quarter; Adjusted Earnings Were $3.16 Per Share for 2007 and $0.79 Per Share for the Fourth Quarter
10. Masimo Reports Fourth Quarter 2007 and Full Year 2007 Financial Results
11. eResearchTechnology Reports Fourth Quarter and Full Year 2007 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... TAIPEI , Jan. 15, 2014 TaiGen Biotechnology ... an exclusive agreement with R-Pharm, a leading Russian pharmaceutical ... in the Russian Federation , ... Commonwealth Independent States (CIS). Nemonoxacin is a novel antibiotic for ...
(Date:1/14/2014)... Histogen, Inc., a regenerative medicine company ... under simulated embryonic conditions, today announced that they have ... Inc. for physician-dispensed aesthetic products containing Histogen’s proprietary multipotent ... is an amendment to the existing license between Histogen ...
(Date:1/14/2014)... January 14, 2014 EquitiesIQ, a leading ... (OTCQB: ALQA). Alliqua is an emerging biomedical company acquiring, ... wound care market. , Free report download: http://equitiesiq.com/reports/alliqua/ ... a seasoned management team and Board, which launched the ...
(Date:1/14/2014)... MA (PRWEB) January 14, 2014 iLab Solutions, ... Detwiler as the new Director of Product Strategy. In this ... well as iLab sub-teams to guide in the development of ... iLab provides the maximum possible benefit to the scientific community ...
Breaking Biology Technology:TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 2TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 3TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 4Histogen and Suneva Medical Expand License for Cell Conditioned Media-based Aesthetic Products Internationally 2Histogen and Suneva Medical Expand License for Cell Conditioned Media-based Aesthetic Products Internationally 3EquitiesIQ Initiates Coverage of Alliqua, Inc. 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 3iLab Solutions Announces Michelle Detwiler as the New Director of Product Strategy 2
... Toronto Stock Exchange Symbol: MS, EDMONTON, June 12 /PRNewswire-FirstCall/ - ... multiple sclerosis (MS), today,announced that Mr. Kevin Giese, President and CEO, ... in San Diego,California., WHEN: ... (PDT), WHERE: ...
... June 12 Repligen Corporation,(Nasdaq: RGEN ) today ... ended March 31, 2008. Total revenue for fiscal year ... fiscal year 2007,ended March 31, 2007, an increase of ... of Protein A and SecreFlo(R) product revenue., Operating ...
... concerning the,economic and business growth in the Tampa Bay ... To Connect Tampa Bay With Mexico, South America, ... cargo service every 60,days between the Port of Tampa ... and Iquitos, Peru. Headquartered in,Lima, Peruvian Amazon Line has ...
Cached Biology Technology:BioMS Medical to present at 2008 BIO International Convention 2Repligen Reports Fourth Quarter and Fiscal Year 2008 Financial Results 2Repligen Reports Fourth Quarter and Fiscal Year 2008 Financial Results 3Repligen Reports Fourth Quarter and Fiscal Year 2008 Financial Results 4Repligen Reports Fourth Quarter and Fiscal Year 2008 Financial Results 5Repligen Reports Fourth Quarter and Fiscal Year 2008 Financial Results 6Repligen Reports Fourth Quarter and Fiscal Year 2008 Financial Results 7Repligen Reports Fourth Quarter and Fiscal Year 2008 Financial Results 8Highlights of Economic and Business Growth in the Tampa Bay Region 2Highlights of Economic and Business Growth in the Tampa Bay Region 3
(Date:4/24/2014)... bacteria attack plants, they often inject harmful proteins ... suppress natural defenses. However, in some plants, bacteria ... a potential host. Now, researchers at the University ... that allows the bacteriaknown mostly for attacking tomatoesto ... natural anti-infective treatments that work with food-producing plants ...
(Date:4/24/2014)... April 24, 2014GEN Publishing recently introduced ... focusing on the application of OMICs technologies in ... sequencing, are beginning to transform medical care just ... the past decade-and-a-half. , "GEN,s editors and reporters ... genomics, metabolomics, transcriptomics, etc. etc. for years," said ...
(Date:4/24/2014)... 24, 2014D-ribose is a commercially important sugar used ... a starting compound for synthesizing riboflavin and several ... to increase the bacteria,s ability to produce ... efficient industrial-scale production of this valuable chemical, as ... , a peer-reviewed journal from Mary Ann Liebert, ...
Breaking Biology News(10 mins):Plants send out signals attracting harmful bacteria, MU study finds 2
... her research into single-cell organisms that affect oral health, ... molecular genetics at The University of Texas Health Science ... the 2011 American Society for Microbiology (ASM) Founders Distinguished ... made significant contributions to the society. Goldschmidt joined the ...
... The University of Pennsylvania, Dr. Ron Koder, assistant professor of ... of a team that devised a novel method for producing ... neuroglobin. He was recently awarded a three-year $1.3 million ... artificial blood that can be administered to injured troops on ...
... Biomedical Research Institute (Seattle BioMed) and Northwestern University Feinberg ... the effort to wipe out some of the most ... large structural genomics centers, they,ve experimentally determined 500 three-dimensional ... pathogens, which could potentially lead to new drugs, vaccines ...
Cached Biology News:UTHealth professor to receive service award from American Society for Microbiology 2CCNY professor gets grant to develop 'artificial blood' 2Milestone in fight against deadly disease 2Milestone in fight against deadly disease 3
Total Proteins from over 50 different human Alzheimer, Diabetic, Liver Cirrhosis, and Lupus diseased tissues are available....
... patented technology, the Lone Wolf valve has ... Open proportional valve available on the market. ... repeatable high-speed performance, and ensures maximum accuracy., ... Enhances system control and patient comfort. , ...
... The VSO LF (Low Flow) offers the same ... control for applications where control is critical or ... solenoid-operated valve automates the flow of gas in ... either DC current or pulse width modulation; closed ...
... from non-demolished blood that is ... The donors are not medicated ... maintained on an antibiotic free ... : 85 mg/ml (by Refractometry).Strain: ...
Biology Products: